Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Role of extracellular vesicles as potential diagnostic and/or therapeutic biomarkers in chronic cardiovascular diseases

  • Martín-Ventura, José Luis
  • Roncal Mancho, Carmen
  • Orbe, Josune
  • Blanco-Colio, Luis Miguel
Cardiovascular diseases (CVDs) are the first cause of death worldwide. In recent years, there has been great interest in the analysis of extracellular vesicles (EVs), including exosomes and microparticles, as potential mediators of biological communication between circulating cells/plasma and cells of the vasculature. Besides their activity as biological effectors, EVs have been also investigated as circulating/systemic biomarkers in different acute and chronic CVDs. In this review, the role of EVs as potential diagnostic and prognostic biomarkers in chronic cardiovascular diseases, including atherosclerosis (mainly, peripheral arterial disease, PAD), aortic stenosis (AS) and aortic aneurysms (AAs), will be described. Mechanistically, we will analyze the implication of EVs in pathological processes associated to cardiovascular remodeling, with special emphasis in their role in vascular and valvular calcification. Specifically, we will focus on the participation of EVs in calcium accumulation in the pathological vascular wall and aortic valves, involving the phenotypic change of vascular smooth muscle cells (SMCs) or valvular interstitial cells (IC) to osteoblast-like cells. The knowledge of the implication of EVs in the pathogenic mechanisms of cardiovascular remodeling is still to be completely deciphered but there are promising results supporting their potential translational application to the diagnosis and therapy of different CVDs., This study was funded by the Spanish Ministry of Economy and Competitiveness (PID2019-106814RB-I00), Comunidad Autónoma de Madrid (Complemento II-CM, S2017/BMD-3673), Instituto de Salud Carlos III (ISCiii-FEDER) (IPT17/0019, PI18/01195, PI19/00065 PI19/00128, and RD21/0006/0008) co-funded by European Regional Development Fund “A way to make Europe (ISCiii-FEDER), Spanish Biomedical Research Centre in Cardiovascular Disease (CB16/11/00371 and CB16/11/00333), The Foundation for Applied Medical Research, Universidad de Navarra (Spain) and La Caixa” Banking Foundation (HR17-00247).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Trimethylamine-N-Oxide (TMAO) predicts cardiovascular mortality in peripheral artery disease

  • Roncal Mancho, Carmen
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Ravassa, Susana
  • Fernández-Montero, Alejandro
  • Saenz-Pipaon, Goren
  • Ugarte, Ana
  • Estella-Hermoso de Mendoza, Ander
  • Rodríguez, José Antonio
  • Fernández Alonso, Sebastián
  • Fernández Alonso, Leopoldo
  • Oyarzabal, Julen
  • Páramo, José A.
Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 1-max 102 months). TMAO levels were increased in CLI compared to IC (P < 0.001). Receiver operating characteristic (ROC) curves for severity (CLI) rendered a cutoff of 2.26 µmol/L for TMAO (62% sensitivity, 76% specificity). Patients with TMAO > 2.26 µmol/L exhibited higher risk of cardiovascular death (subhazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and renal function, should be considered when designing therapeutic strategies to control gut-derived metabolites in vascular patients., This work was supported by the Foundation for Applied Medical Research, Universidad de Navarra (Spain); European Fund for Economic and Regional Development (FEDER) funds [FIS PI18/01195], Ministry of Economy and Competitiveness, Institute of Health Carlos III, [CIBER-CV (CB16/11/00371)]. Patrimonio Praga (Mexico) and Virto Group (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Urinary extracellular vesicles for diabetic kidney disease diagnosis

  • Saenz-Pipaon, Goren
  • Echeverría Ilundáin, Saioa
  • Orbe, Josune
  • Roncal Mancho, Carmen
Diabetic kidney disease (DKD) is the leading cause of end stage renal disease (ESRD) in developed countries, affecting more than 40% of diabetes mellitus (DM) patients. DKD pathogenesis is multifactorial leading to a clinical presentation characterized by proteinuria, hypertension, and a gradual reduction in kidney function, accompanied by a high incidence of cardiovascular (CV) events and mortality. Unlike other diabetes-related complications, DKD prevalence has failed to decline over the past 30 years, becoming a growing socioeconomic burden. Treatments controlling glucose levels, albuminuria and blood pressure may slow down DKD evolution and reduce CV events, but are not able to completely halt its progression. Moreover, one in five patients with diabetes develop DKD in the absence of albuminuria, and in others nephropathy goes unrecognized at the time of diagnosis, urging to find novel noninvasive and more precise early diagnosis and prognosis biomarkers and therapeutic targets for these patient subgroups. Extracellular vesicles (EVs), especially urinary (u)EVs, have emerged as an alternative for this purpose, as changes in their numbers and composition have been reported in clinical conditions involving DM and renal diseases. In this review, we will summarize the current knowledge on the role of (u)EVs in DKD., This research was funded by “Instituto de Salud Carlos III-FEDER,” Fondo de Investigaciones Sanitarias [PI18/01195] and CIBERCV (CB16/11/00371). G.S.-P. was funded with a PhD scholarship from The Foundation for Applied Medical Research, Universidad de Navarra (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

The role of circulating biomarkers in peripheral arterial disease

  • Saenz-Pipaon, Goren
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • González Miqueo, Arantxa
  • Fernández Alonso, Leopoldo
  • Páramo, José A.
  • Roncal Mancho, Carmen
Peripheral arterial disease (PAD) of the lower extremities is a chronic illness predominantly of atherosclerotic aetiology, associated to traditional cardiovascular (CV) risk factors. It is one of the most prevalent CV conditions worldwide in subjects >65 years, estimated to increase greatly with the aging of the population, becoming a severe socioeconomic problem in the future. The narrowing and thrombotic occlusion of the lower limb arteries impairs the walking function as the disease progresses, increasing the risk of CV events (myocardial infarction and stroke), amputation and death. Despite its poor prognosis, PAD patients are scarcely identified until the disease is advanced, highlighting the need for reliable biomarkers for PAD patient stratification, that might also contribute to define more personalized medical treatments. In this review, we will discuss the usefulness of inflammatory molecules, matrix metalloproteinases (MMPs), and cardiac damage markers, as well as novel components of the liquid biopsy, extracellular vesicles (EVs), and non-coding RNAs for lower limb PAD identification, stratification, and outcome assessment. We will also explore the potential of machine learning methods to build prediction models to refine PAD assessment. In this line, the usefulness of multimarker approaches to evaluate this complex multifactorial disease will be also discussed., This research was funded by “Instituto de Salud Carlos III-FEDER,” Fondo de Investigaciones Sanitarias [PI18/01195] and CIBERCV (CB16/11/00371 and CB16/11/00483). G.S.-P. was funded with a Ph.D. scholarship from The Foundation for Applied Medical Research, Universidad de Navarra (Spain).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Role of LCN2 in a murine model of hindlimb ischemia and in peripheral artery disease patients, and its potential regulation by miR-138-5P

  • Saenz-Pipaon, Goren
  • Jover, Eva
  • Van der Bent, M. Leontien
  • Orbe, Josune
  • Rodríguez, José Antonio
  • Fernández Celis, Amaya
  • Quax, Paul H.A.
  • Páramo, José A.
  • López Andrés, Natalia
  • Martín-Ventura, José Luis
  • Nossent, Anne Yäel
  • Roncal Mancho, Carmen
Background and aims: Peripheral arterial disease (PAD) is a leading cause of morbimortality worldwide. Lipocalin-2 (LCN2) has been associated with higher risk of amputation or mortality in PAD and might be involved in muscle regeneration. Our aim is to unravel the role of LCN2 in skeletal muscle repair and PAD. Methods and results: WT and Lcn2 / mice underwent hindlimb ischemia. Blood and crural muscles were analyzed at the inflammatory and regenerative phases. At day 2, Lcn2 / male mice, but not females, showed increased blood and soleus muscle neutrophils, and elevated circulating pro-inflammatory monocytes (p <0.05), while locally, total infiltrating macrophages were reduced (p <0.05). Moreover, Lcn2 / soleus displayed an elevation of Cxcl1 (p <0.001), and Cxcr2 (p <0.01 in males), and a decrease in Ccl5 (p <0.05). At day 15, Lcn2 deficiency delayed muscle recovery, with higher density of regenerating myocytes (p <0.04) and arterioles (αSMA+, p <0.025). Reverse target prediction analysis identified miR-138-5p as a potential regulator of LCN2, showing an inverse correlation with Lcn2 mRNA in skeletal muscles (rho =-0.58, p <0.01). In vitro, miR-138-5p mimic reduced Lcn2 expression and luciferase activity in murine macrophages (p <0.05). Finally, in human serum miR-138-5p was inversely correlated with LCN2 (p ≤0.001 adjusted, n =318), and associated with PAD (Odds ratio 0.634, p =0.02, adjusted, PAD n =264, control n =54). Conclusions: This study suggests a possible dual role of LCN2 in acute and chronic conditions, with a probable role in restraining inflammation early after skeletal muscle ischemia, while being associated with vascular damage in PAD, and identifies miR-138-5p as one potential post-transcriptional regulator of LCN2., The Foundation for Applied Medical Research, Universidad de Navarra (Spain); the Ministry of Science and Innovation, Institute of Health Carlos III, co-funded by the European Fund for Economic and Regional Development (FEDER) [PI18/01195], This research was supported by CIBER -Consorcio Centro de Investigación Biomédica en Red- Cardiovascular (CB16/11/00483 and CB16/11/00333), Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación. Virto Group (Spain). This work was supported by a Short-Term Scientific Mission from COST Action CA17129 funded by COST (European Cooperation in Science and Technology).
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Lipocalin-2 and calprotectin potential prognosis biomarkers in peripheral arterial disease

  • Saenz-Pipaon, Goren
  • Ravassa, Susana
  • Larsen, Katrine L.
  • Martínez Aguilar, Esther
  • Orbe, Josune
  • Rodríguez, José Antonio
  • Fernández Alonso, Leopoldo
  • González, Arantxa
  • Martín-Ventura, José Luis
  • Páramo, José A.
  • Lindholt, Jes S.
  • Roncal Mancho, Carmen
Objective: Peripheral arterial disease (PAD) is the most prevalent cardiovascular (CV) condition globally. Despite the high CV risk of PAD patients, no reliable predictors of adverse clinical evolution are yet available. In this regard, previous transcriptomic analyses revealed increased expression of calprotectin (S100A8/A9) and lipocalin-2 (LCN2) in circulating extracellular vesicles (EVs) of patients with PAD. The aim of this study was to determine the prognostic value of LCN2 and calprotectin for CV risk assessment in PAD. Methods: LCN2 and the S100A9 subunit of calprotectin were examined in human femoral plaques by immunohistochemistry and qPCR. LCN2 and calprotectin were determined by ELISA in PAD (CHN cohort, n ¼ 331, Fontaine IIeIV, serum), and PAD diagnosed by population based screening (VIVA trial, n ¼ 413, the majority Fontaine 0eI, plasma). Patients were followed up for a mean of four years, recording the primary outcomes; CV death or amputation in the CHN cohort and CV death or major lower limb events (MALE) in the VIVA population. Secondary outcomes were all cause death or amputation, and all cause death or MALE, respectively. Results: LCN2 and S100A9 were detected in human plaques in regions rich in inflammatory cells. LCN2 and calprotectin levels were 70% and 64% lower in plasma than in serum. In the CHN cohort, high serum levels of LCN2 and calprotectin increased the risk of primary and secondary outcomes 5.6 fold (p < .001) and 1.8 fold (p ¼ .034), respectively, after covariable adjustment. Similarly, elevated plasma levels of LCN2 and calprotectin increased by three fold the risk of primary and secondary outcomes (p < .001) in the VIVA cohort. Moreover, addition of the combined variable to basal models, considering clinically relevant risk factors, improved reclassification for the primary outcome in both cohorts (p .024). Conclusion: Combined assessment of the inflammatory biomarkers LCN2 and calprotectin might be useful for risk stratification in advanced and early PAD., The Foundation for Applied Medical Research, Universidad de Navarra (Spain); Ministry of Science and Innovation, Institute of Health Carlos III, co-funded by the European Fund for Economic and Regional Development (FEDER) [PI18/01195], Ministry of Science and Innovation, Institute of Health Carlos III [CB16/11/00371 and CB16/11/00483] and VIRTO group.